Western Isles prescribes 10 times more than Shetland, and the ABPI says need doesn't explain the gap. It also found 71% of Scots on weight loss drugs went private.
Recap by typeshit. Full story at Radio News Hub.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
The review lays out how GLP-1 agonists may affect blood pressure and lipid handling, and why that could matter for heart risk.
Varon says some of his patients still have diarrhea after meals years after stopping, though the interview didn't show the drugs caused it. He also points to thyroid findings in animals.
Loading…